morniflumate

Morniflumate is a non-steroidal anti-inflammatory drug (NSAID) and the morpholinoethyl ester of niflumic acid. It is used primarily for the symptomatic treatment of inflammatory conditions affecting the airways, ear-nose-throat (ENT) system, urogenital tract, and osteoarticular (bone and joint) systems in adults. In Italy, it is also indicated for pain associated with ENT and gastrointestinal inflammatory conditions in children. Morniflumate has been marketed for over three decades in several European countries including Italy, France, Belgium, Austria, Switzerland, Spain, and Portugal[2][5][7]. Its mechanism of action involves inhibition of cyclooxygenase (COX), particularly COX-2; it also inhibits 5-lipoxygenase and phospholipase A2—key enzymes involved in arachidonic acid metabolism—thereby reducing synthesis of proinflammatory prostaglandins and leukotrienes[1][6][8]. Morniflumate demonstrates anti-inflammatory, analgesic (pain-relieving), and antipyretic properties with a favorable tolerability profile compared to its parent compound niflumic acid due to reduced gastric irritation[1][5].

Other names

2-morpholin-4-ylethyl 2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylate